Nuvation Bio's IBTROZI Demonstrates Strong Commercial Performance with 432 New Patients in First Six Months
核心洞察
Nuvation Bio reported 432 new patients started on IBTROZI (搜索) (taletrectinib) since its June 2025 launch, with treatment adoption rates approximately six times greater than prior ROS1 (搜索) tyrosine kinase inhibitor launches.
The company generated $24.7 million in preliminary net product revenue from IBTROZI (搜索) since launch, including $15.7 million in the fourth quarter of 2025.
IBTROZI (搜索) has become the preferred treatment for advanced ROS1-positive non-small cell lung cancer (搜索) across treatment lines, demonstrating an impressive duration of response of over four years.
Nuvation Bio Inc. reported strong commercial performance for its recently launched ROS1 (搜索) inhibitor IBTROZI (搜索) (taletrectinib), with 432 new patients starting treatment since the drug's approval in June 2025. The company announced preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Rapid Market Adoption Exceeds Expectations
IBTROZI (搜索) demonstrated exceptional market uptake, with 216 new patients starting treatment in the fourth quarter of 2025, exceeding internal projections despite holiday-adjacent weeks that typically limit new patient starts in rare diseases. This followed 204 new patient starts in the third quarter, the company's first full quarter of sales.
The treatment adoption rate is approximately six times greater than that of prior recent ROS1 (搜索) tyrosine kinase inhibitor launches based on IQVIA data, according to the company. This rapid adoption reflects what CEO David Hung, M.D., described as confidence in "IBTROZI (搜索)'s impressive duration of response of over four years and its manageable safety profile."
Strong Financial Performance
Preliminary IBTROZI (搜索) net product revenue reached $15.7 million in the fourth quarter and $24.7 million since launch. The company also received a $25 million milestone payment from Nippon Kayaku (搜索) following establishment of the reimbursement price in Japan during the fourth quarter.
Nuvation Bio maintained a robust financial position with preliminary unaudited cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025.
International Expansion Through Strategic Partnership
On January 11, 2026, Nuvation Bio entered an exclusive license and collaboration agreement with Eisai Co., Ltd. to develop, register and commercialize taletrectinib for ROS1 (搜索)-positive NSCLC treatment across multiple international markets including Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India.
Clinical Profile and Market Position
IBTROZI (搜索) is an oral, potent, CNS-active, selective, next-generation ROS1 (搜索) inhibitor therapy that received FDA approval on June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naïve and TKI-pretreated disease. The drug is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (搜索).
"In just two full quarters of commercial launch, IBTROZI (搜索) is now the preferred TKI for people living with advanced ROS1 (搜索)+ NSCLC and their healthcare providers, becoming the new standard of care across treatment lines," said Hung.
Addressing Significant Unmet Medical Need
ROS1 (搜索)-positive NSCLC affects approximately 2% of the more than one million people globally diagnosed with non-small cell lung cancer annually. About 35% of patients newly diagnosed with metastatic ROS1-positive NSCLC have tumors that have spread to their brain, and the brain is the most common site of disease progression, with about 50% of previously treated patients developing central nervous system metastases.
Safety Profile
The most frequently reported adverse reactions (≥20%) among patients receiving IBTROZI (搜索) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).
Pipeline Development
Beyond IBTROZI (搜索), Nuvation Bio continues advancing its pipeline, including ongoing enrollment in the G203 phase 3 registration-enabling study evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas (搜索). The company is also conducting ongoing evaluation of preclinical candidates from its drug-drug conjugate platform.
2026 Outlook
For 2026, Nuvation Bio plans to continue growing IBTROZI (搜索) new patient starts in advanced ROS1 (搜索)-positive NSCLC, particularly in the first-line setting, while supporting continuity of therapy for current patients. The company will also pursue business development opportunities to expand its pipeline and maintain its robust cash position to support continued investment in future growth.